Purespring Therapeutics

Purespring, which launched in November 2020 with 45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases

Biotechnology,gene therapy,and kidney diseases

Purespring therapeutics operates in the Biotechnology research industry.

Purespring therapeutics's revenue is 11m - 100m

Purespring therapeutics has 51 - 200 employees.